Woburn, Massachusetts, February 21, 2024 — PAR Clinical, a Boston based “Strategic life sciences consulting firm” and Inductive Quotient Analytics Inc (IQA), a “clinical technology company” specializing in biometrics services and clinical AI platforms, are thrilled to announce their strategic collaboration to enhance each other’s capabilities and expand our strategic offerings to our clients.

About PAR Clinical

PAR Clinical is a “Strategic life sciences consulting firm” and has been at the forefront of offering functional expertise, objective analysis, on-demand resources, and execution of clinical studies as a full-service model under one single umbrella utilizing our trademark SPEO model. 

About Inductive Quotient Analytics Inc (IQA)

IQA is revolutionizing clinical research and trials through cutting-edge technologies such as artificial intelligence (GenAI) and machine learning (ML). Their team of experts accelerates the development of new therapies while reducing costs and improving patient outcomes.

The Collaboration

The collaboration between PAR Clinical and IQA aims to:

  1. Expand Service Offerings: By leveraging IQA’s GenAI-driven biometrics services, PAR Clinical through its trademark SPEO model will optimize clinical trial data management, making significant strides in reducing timelines to achieve clinical trial milestones. Similarly, IQA’s team will leverage the full-service SPEO capabilities of PAR Clinical and expand their offerings in North America. 
  2. Streamline Processes: IQA’s and PAR Clinical’s combined expertise in decentralized clinical trials and data mining will redefine how studies are planned and conducted, ensuring patient-centric approaches and efficient processes.
  3. Data-Driven Insights: Biostatistics and advanced analytics from IQA will build trust in drug discovery, providing actionable insights for better healthcare outcomes.
  4. Global FSP Expertise:This model merges FSP capabilities of IQA with PAR Clinical’s SPEO Model, optimizing offshore/onshore to deliver full-service CRO capabilities. It ensures efficient, strategic collaboration, driving innovation and cost-effectiveness in project execution.

Joint Statement

Sid Parulkar, M. Pharm, CEO of PAR Clinical, expressed his excitement: “Our collaboration with IQA aligns perfectly with our mission to provide cutting-edge solutions to our clients utilizing their Gen AI technology to support our current needs in bio-metrics segment. Our shared vision of becoming a major player with early-stage biopharmaceutical drug development companies played a critical role in collaborating and expanding our offerings to our clients.”

Ramaiah Muvvala, Founder and CTO of IQA, added: “We believe that combining PAR Clinical’s domain expertise in early-stage drug development with IQA’s expertise in Biometrics services and technological prowess will unlock new possibilities in clinical trials. Our shared commitment to continue building efficiencies in management of clinical trials will reduce time to market for drugs in development.”

Looking Ahead

The PAR Clinical and IQA teams are already working on joint initiatives, including AI-powered data analysis, decentralized trial strategies, and seamless integration of biometrics services.


For media inquiries, please contact:

Sid Parulkar, CEO PAR Clinical LLC 

Email: [email protected]. 

Phone +1 (919) 607-9071

Manoj Velladandi, Director – Biometrics and Presales 

Email: [email protected]. 

Phone +1 (774) 423 -9476

Stay tuned for updates as we embark on this exciting journey of innovation and impact.

  Note to Editors: High-resolution logos and images are available upon request.

1: www.parclinical.com

2: Inductive Quotient Analytics Inc

This press release is not an endorsement or recommendation of any product or service.